Nektar Therapeutics (Nasdaq: NKTR) announced today that data from the ongoing Phase 2b studies of rezpegaldesleukin in atopic ...
Hello, and welcome to the Life Science Investor Forum . On behalf of OTC Markets and our co-host, Zacks Small Cap Research , we are very pleased you have joined us. The next presentation of the day is ...
Public Safety Director Adrian Karr presented the Honors Board of Review recipients, which ranged from the teamwork needed to keep the hospital lights on during a destructive ice storm to rescuing an ...
NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravis Aarhus, Denmark, 10 March 2026 - NMD Pharma A/S, a clinical-sta ...
Two international studies, a clinical trial led by the University of Oxford and University of Utrecht, and a qualitative ...
New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten) ...
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts ...
How dining environments support cognitive health in long-term care. Learn how RDs can enhance autonomy, socialization, and ...
H. Lundbeck A/S (Lundbeck) today announced that new data from a Phase 1b proof-of-mechanism trial of Lu AF28996, a novel compound invented by Lundbeck with dopamine D1/D2 receptor agonist activity, ...
Positive data from EXPERTS-ALS could accelerate RT1999 towards a registration trial; RT1999 to be presented as a poster ...
Q4 2025 Earnings Call March 12, 2026 4:30 PM EDTCompany ParticipantsJennie WillsonJacqueline Shea - CEO, President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results